This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

QUOSA And Copyright Clearance Center Expand Access To Compliant Literature With Integrated Rights Management

Stocks in this article: REN ENL RUK

AMSTERDAM, July 23, 2014 /PRNewswire/ --

QUOSA now offers customers with CCC licenses the full benefits of integration at no extra cost, significantly lowering barriers to copyright compliance 

Elsevier, a world-leading provider of scientific, technical and medical information products and services, today announced that QUOSA, its literature management solution, and Copyright Clearance Center (CCC) have extended their relationship to support greater compliance in the use of full text articles within corporate or institutional environments. Using CCC's rights advisory API, QUOSA customers who are also CCC licensees can view their license rights directly from QUOSA at no extra cost to the user.

QUOSA users can instantly check the usage rights of documents within the QUOSA library by accessing the CCC database via a single user interface, helping them to quickly determine how they may use a document; for example, checking if they can share an article with colleagues. This significantly increases the efficiency of content management workflows, helping users manage large libraries of information and ensure compliance requirements are met. QUOSA and CCC first partnered in 2009; the expansion of this relationship will now deliver the same seamless functionality at no extra cost.

"Ensuring compliance is a mammoth task for both researchers and Information Managers alike. Users need to be sure they are using documents in a compliant manner and Information Managers must avoid the significant financial penalties that can result from failed compliance," said Daan de Jong, Director Product Development for Elsevier. "This latest enhancement to QUOSA supports our drive to make QUOSA the 'one stop shop' for literature management. Integrating QUOSA with per-article rights data at no extra cost takes away the uncertainty surrounding compliance that is experienced by pharmacovigilance and medical affairs personnel when accessing scientific literature."

QUOSA is a centralized repository of scientific literature that enables life sciences institutions to meet regulatory reporting requirements, address medical inquiries and maintain current awareness in relation to topics or authors. It is used by a broad array of groups such as pharmacovigilance and medical affairs personnel in pharma, biotech and medical device companies. CCC is a leading global rights-licensing technology organization, providing solutions that simplify compliance for content users, promoting the work of creators and supporting the principles of copyright.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Jim Cramer and Stephanie Link reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

Jim Cramer's protégé, David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
Try it NOW
Try it NOW
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

Jim Cramer's protégé, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,678.70 +6.10 0.03%
S&P 500 2,057.09 +5.27 0.26%
NASDAQ 4,771.7630 +13.8840 0.29%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs